Deucrava contains Deucravacitinib, a selective tyrosine kinase 2 (TYK2) inhibitor designed for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. By selectively targeting TYK2, Deucrava modulates immune signaling pathways implicated in psoriasis, helping reduce inflammation and the excessive skin cell proliferation characteristic of the disease. It is not recommended to be used in combination with other potent immunosuppressants.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Therapeutic Class

• Tyrosine Kinase Inhibitor

• Drugs for Plaque Psoriasis / Immunomodulatory Therapy

Indications

Deucrava is indicated for:

• Treatment of moderate-to-severe plaque psoriasis in adult patients who require systemic therapy or phototherapy.

• Not recommended for use with other potent immunosuppressive medications.

Pharmacology / Mode of Action

Deucravacitinib selectively inhibits TYK2, a member of the Janus kinase (JAK) family, by binding to its regulatory domain. This stabilizes an inhibitory interaction between the regulatory and catalytic domains of the enzyme, preventing downstream activation of Signal Transducers and Activators of Transcription (STATs). TYK2 normally pairs with JAK1 or JAK2 to transmit multiple cytokine signals involved in inflammatory responses. By selectively inhibiting TYK2, Deucrava modulates cytokine pathways implicated in psoriasis, reducing inflammation and skin lesion formation.

Dosage and Administration

• Recommended Dose: 6 mg orally once daily, with or without food.

• Tablet Instructions: Do not crush, cut, or chew the tablet.

• Pediatric Use: Safety and efficacy in children have not been established.

• Elderly: No differences in effectiveness compared to younger adults.

• Hepatic Impairment: Not recommended in severe hepatic impairment (Child-Pugh C); no adjustment for mild-to-moderate impairment.

• Renal Impairment: No dose adjustment required, including in patients with end-stage renal disease on dialysis.

• Pre-Treatment Evaluation: Screen for active or latent tuberculosis prior to initiating therapy. Treat TB before starting Deucrava if positive.

Drug Interactions

• No clinically significant pharmacokinetic interactions observed with cyclosporine, fluvoxamine, ritonavir, diflunisal, pyrimethamine, famotidine, or rabeprazole.

• No significant impact on rosuvastatin, methotrexate, mycophenolate mofetil, or oral contraceptives when co-administered with Deucrava.

Contraindications

• Hypersensitivity to Deucravacitinib or any excipient in the formulation.

Side Effects

Common adverse effects include:

• Upper respiratory infections (common cold, sore throat, sinus infection)

• Herpes simplex (cold sores)

• Oral ulcers (canker sores)

• Folliculitis and acne

• Serious allergic reactions: swelling of face, lips, mouth, throat, trouble breathing, hives, or chest tightness

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Precautions and Warnings

• Monitor for hypersensitivity reactions; discontinue if significant.

• Increased risk of infection; avoid use in active or serious infections.

• Screen for tuberculosis before starting treatment.

• Monitor serum triglycerides and liver enzymes, especially in patients with liver disease.

• Avoid use with live vaccines.

• TYK2 inhibition may carry risks similar to JAK inhibitors, including cardiovascular events, thrombosis, malignancies, rhabdomyolysis, and elevated CPK.

Pregnancy and Lactation

• Pregnancy Category: Data insufficient; use only if clearly necessary.

• Animal studies showed no embryo-fetal development effects.

• No data on excretion in human milk; weigh benefits of breastfeeding against clinical need.

Storage Conditions

• Store below 30°C, away from light and moisture.

• Keep out of reach of children.